Consequences of delaying treatment intensification in type 2 diabetes: evidence from a UK database

References

• WHO Fact Sheet 312. Available at: http://www.who.int/mediacentre/factsheets/fs312/en/ [Last accessed June 2015]
   Google Scholar
• Diabetes UK. Diabetes Facts and Stats March 2014. Available at: https://www.diabetes.org.uk. Accessedd June 2015
   Google Scholar
• Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352(UKPDS 33):837-53
   PubMedGoogle Scholar
• NICE Clinical Guideline 87. Available at: https://www.nice.org.uk/guidance/cg87 [Last accessed June 2015]
   Google Scholar
• Calvert MJ, McManus RJ, Freemantle N. Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study. Br J Gen Pract 2007;57:455-60
   PubMed Web of Science ®Google Scholar
• Goudswaard AN, Stolk RP, Zuithoff P, Rutten GEHM. Patient characteristics do not predict poor glycaemic control in type 2 diabetes patients treated in primary care. Eur J Epidemiol 2004;19:541-5
   PubMed Web of Science ®Google Scholar
• Rodondi N, Peng T, Karter AJ, et al. Therapy modifications in response to poorly controlled hypertension, dyslipidemia and diabetes mellitus. Ann Intern Med 2008;144:475-84
   Web of Science ®Google Scholar
• Lafata JE, Dobie EA, Divine GW, et al. Sustained hyperglycemia among patients with diabetes: What matters when action is needed? Diabetes Care. 2009;32:1447-52
   PubMed Web of Science ®Google Scholar
• Fu A, Qiu Y, Davies M, et al. Treatment intensification in patients with type 2 diabetes who failed metformin monotherapy. Diabetes Obes Metab 2011;13:765-9
   PubMed Web of Science ®Google Scholar
• Guisasola FÁ, Mavros P, Nocea G, et al. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study. Diabetes Obes Metab 2008;10(Suppl 1):8-15
   PubMed Web of Science ®Google Scholar
• Riedel AA, Heien H, Wogen J, Plauschinat CA. Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy. Pharmacotherapy 2007;27:1102-10
   PubMed Web of Science ®Google Scholar
• Health & Social Care Information Centre (HSSIC). Healthcare Quality Improvement (HQIP) Report. National Diabetes Audit 2012–2013. Report 1 – Care Processes and Treatment Targets.
   Google Scholar
• Khunti K, Wolden ML, Thorsted BL, et al. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care 2013;36:3411-17
   PubMed Web of Science ®Google Scholar
• Paul SK, Thorsted BL, Wolden ML, et al. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovascular Diabetology 2015;14:100
   PubMed Web of Science ®Google Scholar
• Bailey CJ. The current drug treatment landscape for diabetes and perspectives for the future. Clin Pharm Therapeut 2015;98:170-84
   Web of Science ®Google Scholar
• Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the general practice research database. Pharmacotherapy 2003;23:686-9
   PubMed Web of Science ®Google Scholar
• NHS Reference Costs. Available at: https://www.gov.uk/government/publications/nhs-reference-costs-2012-to-2013 [Last accessed June 2015]
   Google Scholar
• Personal Social Services Research Unit (PSSRU). Unit costs of health and social care. Available at: http://www.pssru.ac.uk/project-information [Last accessed June 2015]
   Google Scholar
• Millett C, Gray J, Saxena S, et al. Ethnic disparities in diabetes management and pay-for-performance in the UK: the Wandsworth Prospective Diabetes Study. PLoS Med 2007;4:e191
   PubMedGoogle Scholar
• Leal I, Romio SA, Schuemie M, et al. Prescribing pattern of glucose lowering drugs in the United Kingdom in the last decade: a focus on the effects of safety warnings about rosiglitazone. Br J Clin Pharmacol 2013;75:861-8
   PubMed Web of Science ®Google Scholar
• Ahrén B. Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vasc Health Risk Manag 2013;9:155-63
   PubMedGoogle Scholar
• Wami WM, Buntinx F, Bartholomeeusen S, et al. Influence of chronic comorbidity and medication on the efficacy of treatment in patients with diabetes in general practice. Br J Gen Pract 2013;63:e267-73
   PubMed Web of Science ®Google Scholar
• Morgan J. Classification and Regression Tree Analysis. Report No1. Boston University School of Public Health, 2014
   Google Scholar
• Lewis G, Maxwell A. Risk factor control is key in diabetic nephropathy. Practitioner 2014;258:13-72
   PubMedGoogle Scholar
• Cetin S, Oztürk M, Barındık N, et al. Increased coronary intervention rate among diabetic patients with poor glycaemic control: a cross-sectional study. Bosn J Basic Med Sci 2014;14:16-20
   PubMed Web of Science ®Google Scholar
• Shah B, Hux J, Laupacis A, et al. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? Diabetes Care 2005;28:600-60
   PubMed Web of Science ®Google Scholar
• Rosenthal M, Fajardo M, Gilmore S, et al. Hospitalization and mortality of diabetes in older adults. A 3-year prospective study. Diabetes Care 1998;21:231-5
   PubMed Web of Science ®Google Scholar
• Goring S, Hawkins N, Wygant G, et al. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. Diabetes Obes Metab 2014;16:433-42
   PubMed Web of Science ®Google Scholar
• UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007;50:1140-7
   PubMed Web of Science ®Google Scholar
• Sapkota S, Brien J, Greenfield J, Aslani P. A systematic review of interventions addressing adherence to anti-diabetic medications in patients with type 2 diabetes – impact on adherence. PLoS One 2015;10:e0118296
   PubMed Web of Science ®Google Scholar
• Lawrence DB, Ragucci KR, Long LB, et al. Relationship of oral antihyperglycemic (sulphonylurea or metformin) medication adherence and hemoglobin A1c goal attainment for HMO patients enrolled in a diabetes disease management program. J Manag Care Pharm 2006;12:466-71
   PubMed Web of Science ®Google Scholar
• Ramirez A, Wolfsgruber S, Lange C, et al. Elevated HbA1c is associated with increased risk of incident dementia in primary care patients. J Alzheimers Dis 2015;44:1203-12
   PubMed Web of Science ®Google Scholar
• Seuring T, Archangelidi O, Suhrcke M. The economic costs of type 2 diabetes: a global systematic review. PharmacoEconomics 2015;33:811-31
   Google Scholar
• Ng C, Lee J, Toh M, Ko Y. Cost-of-illness studies of diabetes mellitus: a systematic review. Diabetes Res Clin Pr 2014;105:151-63
   PubMed Web of Science ®Google Scholar